Immix Biopharma Investor Presentation Deck

NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Multiple Myeloma Patients Clinical Data No Prior BCMA-Targeted Therapy Patient #s Extramedullary disease (EMD) High risk cytogenetics Overall Response Rate Complete Response Rate ICANS Neurotoxcity (all grades) CRS, grade >= 3 Potential hospital stay length based on available data Source NEXCELLA HEXATION CLL THE planned RP2D 800 million CAR+T cells NXC-201 Monotherapy n=38 24% 62% 95% 61% -3 days 49th EBMT Meeting 2023 20th IMS Meeting 2023 ARCELLX (NASDAQ: ACLX) CART- ddBCMA 100 + 300M cells n=31 39% 100% 71% 23% 3% -14 days 2022 NASDAQ IPO S-1 Johnson Johnson CARVYKTI fittacattajent autoleucell n=97 13% 24% 98% 78% 23% (2 deaths) 5% (1 death) -14 days FDA Approval Label Bristol Myers Squibb Abecma lidecatogene videoe n=144 50% 36% 88% 48% 8.5% -14 days Ferreri et al, Blood 2022 NEXCELLA Yes Prior BCMA-Targeted Therapy planned RP2D 800 million CAR+T cells NXC-201 Monotherapy n=12 24% 62% 75% 50% 0% -3 days 49th EBMT Meeting 2023 Investigator's choice N=275 ? 29% 31% 2% N/A N/A N/A Gandhi, et al 2019 Johnson Johnson CARVYKTI (citacabtagere autoleucel n=20 25% 15% 60% 30% 20% 0% -14 days Blood 2023 - Cohen et al Bristol Myers Squibb Abecma (decabtogene vicleuce) n=49 50% 36% 74% 29% 8.5% 2% -14 days Ferreri et al, Blood 2022 Overall - Mixed (BCMA Pretreated + not) NEXCELLA HET GENERATION CELL THERAP includes all patients (with and without Prior BCMA-Targeted Therapy) treated at 800 million CAR+T cells NXC-201 Monotherapy n=50 24% 62% 90% 58% 4% 14% -3 days ●●● IMMIX S BIOPHARMA 20th IMS Meeting 2023 Ill Bristol Myers Squibb™ Abecma (idecabtagene vicleuce) n=100 36% 37% 72% 28% 28% 9%² (1 death) 14 days FDA Approval Label 176,404 (35,730 US) patient annual incidence ¹All grades of neurotoxicity 2 The safety data described in this section reflect the exposure to ABECMA in the KarMMa study, in which 127 patients with relapsed/refractory multiple myeloma received ABECMA. 3a3bFor of the first 20, 42 patients treated with NXC-201 at all doses, respectively Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421, Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221., Point-of-care CART manufacture and delivery: zExpanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9- 11. Assayag M, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26. Blood 2022 https://doi.org/10.1182/blood-2022-164884. Cohen et al 2023 34 https://doi.org/10.1182/blood.2022015526. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.

View entire presentation